CTOR · Citius Oncology, Inc.
$0.74
-0.02 (-2.02%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$69.16M
Shares
92.98M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$24.76M
-17.1%
FY2025
Diluted EPS
-$0.34
-9.7%
FY2025
Operating Cash Flow
-$5.49M
-4446.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $3.39M | $6.42M | $4.93M | $4.24M | — | |
| $32.04M | $8.78M | $8.15M | $1.01M | $138.12K | |
| $52.79M | $23.52M | $20.57M | $12.12M | — | |
| -$47.29M | -$23.52M | -$20.57M | -$1.01M | -$138.12K | |
| — | $218.03K | — | — | — | |
| — | $36.37K | — | — | — | |
| — | -$181.66K | — | $3.43M | $518.93K | |
| -$45.87M | -$23.7M | -$20.57M | -$12.12M | — | |
| $189.92K | $1.06M | $576K | $576K | — | |
| -$46.06M | -$24.76M | -$21.15M | $2.42M | $380.81K | |
| USD/shares | — | -$0.34 | -$0.31 | $0.27 | $0.12 |
| USD/shares | — | -$0.34 | -$0.31 | $0.27 | $0.12 |
| shares | — | 73.27M | 68.05M | 6.6M | 1.87M |
| shares | — | 73.27M | 68.05M | 6.6M | 1.34M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.38×
EV/EBIT
—
Peer median 8.66×
P/E (TTM)
—
Peer medians compare against the 45 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).